Publications | PubMed=3940644 Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46:798-806(1986) PubMed=3335022 Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601(1988) PubMed=2388294; DOI=10.1093/jnci/82.17.1420 McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C., Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R. Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines. J. Natl. Cancer Inst. 82:1420-1426(1990) PubMed=2041050; DOI=10.1093/jnci/83.11.757 Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83:757-766(1991) PubMed=1311061 Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180(1992) PubMed=1563005 Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W. Neuromedin B is present in lung cancer cell lines. Cancer Res. 52:2732s-2736s(1992) PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y., Takahashi T., Ueda R. Alterations of integrin expression in human lung cancer. Jpn. J. Cancer Res. 84:168-174(1993) PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur. J. Cancer 31:230-237(1995) PubMed=8626706; DOI=10.1074/jbc.271.19.11477 Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F. Insulin-like growth factor expression in human cancer cell lines. J. Biol. Chem. 271:11477-11483(1996) PubMed=8806092; DOI=10.1002/jcb.240630505 Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L. NCI-Navy Medical Oncology Branch cell line data base. J. Cell. Biochem. 63 Suppl. 24:32-91(1996) PubMed=10358721; DOI=10.18926/AMO/31626 Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K., Kohara H., Harada M. Establishment of a drug sensitivity panel using human lung cancer cell lines. Acta Med. Okayama 53:67-75(1999) PubMed=10700174; DOI=10.1038/73432 Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:227-235(2000) PubMed=11030152; DOI=10.1038/sj.onc.1203815 Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene 19:4632-4639(2000) PubMed=11551417; DOI=10.1016/s0169-5002(01)00205-7 Yoon S.-S., Ahn K.-S., Kim S.-H., Shim Y.M., Kim J. In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype. Lung Cancer 33:221-228(2001) PubMed=11583962; DOI=10.1016/S0002-9440(10)62521-7 Haruki N., Harano T., Masuda A., Kiyono T., Takahashi T., Tatematsu Y., Shimizu S., Mitsudomi T., Konishi H., Osada H., Fujii Y., Takahashi T. Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. Am. J. Pathol. 159:1345-1352(2001) PubMed=12068308; DOI=10.1038/nature00766 Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417:949-954(2002) PubMed=12794755; DOI=10.1002/ijc.11184 Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., Mitsudomi T. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int. J. Cancer 106:45-51(2003) PubMed=15746151; DOI=10.1093/hmg/ddi092 Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum. Mol. Genet. 14:997-1007(2005) PubMed=15748285; DOI=10.1186/1479-5876-3-11 Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M. HLA class I and II genotype of the NCI-60 cell lines. J. Transl. Med. 3:11.1-11.8(2005) PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433 Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5:2606-2612(2006) PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339 Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 67:2046-2053(2007) PubMed=18083107; DOI=10.1016/j.cell.2007.11.025 Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.-M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q., Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203(2007) PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921 Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N. DNA fingerprinting of the NCI-60 cell line panel. Mol. Cancer Ther. 8:713-724(2009) PubMed=19472407; DOI=10.1002/humu.21028 Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M. A gene-alteration profile of human lung cancer cell lines. Hum. Mutat. 30:1199-1206(2009) PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022 Karger A., Bettin B., Lenk M., Mettenleiter T.C. Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing. J. Virol. Methods 164:116-121(2010) PubMed=20164919; DOI=10.1038/nature08768 Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010) PubMed=20510196; DOI=10.1016/j.ijrobp.2009.12.076 Lee Y.S., Oh J.-H., Yoon S., Kwon M.-S., Song C.-W., Kim K.-H., Cho M.-J., Mollah M.L., Je Y.J., Kim Y.-D., Kim C.D., Lee J.-H. Differential gene expression profiles of radioresistant non-small-cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 77:858-866(2010) PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J. Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma. Cancer Sci. 101:1891-1896(2010) PubMed=22068913; DOI=10.1073/pnas.1111840108 Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011) PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017 Kong D., Yamori T. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg. Med. Chem. 20:1947-1951(2012) PubMed=22347499; DOI=10.1371/journal.pone.0031628 Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C. Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location. PLoS ONE 7:E31628-E31628(2012) PubMed=22384151; DOI=10.1371/journal.pone.0032096 Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T. Identification of cancer cell-line origins using fluorescence image-based phenomic screening. PLoS ONE 7:E32096-E32096(2012) PubMed=22460905; DOI=10.1038/nature11003 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012) PubMed=22628656; DOI=10.1126/science.1218595 Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336:1040-1044(2012) PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112 Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2:798-811(2012) PubMed=23381221; DOI=10.3892/or.2013.2266 Suzuki M., Shiraishi K., Eguchi A., Ikeda K., Mori T., Yoshimoto K., Ohba Y., Yamada T., Ito T., Baba Y., Baba H. Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer. Oncol. Rep. 29:1308-1314(2013) PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342 Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 73:4372-4382(2013) PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018 Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4:609-620(2013) PubMed=24135919; DOI=10.1038/ncomms3617 Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G., Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M. Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nat. Commun. 4:2617.1-2617.13(2013) PubMed=24279929; DOI=10.1186/2049-3002-1-20 Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab. 1:20.1-20.13(2013) PubMed=24465237; DOI=10.5808/GI.2013.11.4.245 Im C.-N., Kim B.M., Moon E.-Y., Hong D.-W., Park J.W., Hong S.H. Characterization of H460R, a radioresistant human lung cancer cell line, and involvement of syntrophin beta 2 (SNTB2) in radioresistance. Genomics Inform. 11:245-253(2013) PubMed=24670534; DOI=10.1371/journal.pone.0092047 Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C. High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS ONE 9:E92047-E92047(2014) PubMed=25120651; DOI=10.3892/ol.2014.2234 Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K., Shibata H., Ito T., Baba Y., Baba H. Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer. Oncol. Lett. 8:1025-1030(2014) PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5 Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med. 7:118.1-118.7(2015) PubMed=27377824; DOI=10.1038/sdata.2016.52 Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J. Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR. Sci. Data 3:160052-160052(2016) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016) PubMed=27807467; DOI=10.1186/s13100-016-0078-4 Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H. A map of mobile DNA insertions in the NCI-60 human cancer cell panel. Mob. DNA 7:20.1-20.11(2016) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017) PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051 Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F. Differential effector engagement by oncogenic KRAS. Cell Rep. 22:1889-1902(2018) PubMed=29681454; DOI=10.1016/j.cell.2018.03.028 McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., Deberardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A. Chemistry-first approach for nomination of personalized treatment in lung cancer. Cell 173:864-878.e29(2018) PubMed=30038707; DOI=10.18632/oncotarget.25642 Du L.-Q., Zhao Z.-Z., Suraokar M., Shelton S.S., Ma X.-Y., Hsiao T.-H., Minna J.D., Wistuba I.I., Pertsemlidis A. LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget 9:29601-29618(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=31803961; DOI=10.1002/jcb.29564 Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I., Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M., Aldige C.R., Wistuba I.I., Minna J.D. From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later. J. Cell. Biochem. 121:3986-3999(2020) PubMed=31978347; DOI=10.1016/j.cell.2019.12.023 Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180:387-402.e16(2020) PubMed=33425914; DOI=10.3389/fcell.2020.607275 Lei Z.-N., Teng Q.-X., Zhang W., Fan Y.-F., Wang J.-Q., Cai C.-Y., Lu K.W., Yang D.-H., Wurpel J.N.D., Chen Z.-S. Establishment and characterization of a topotecan resistant non-small cell lung cancer NCI-H460/TPT10 cell line. Front. Cell Dev. Biol. 8:607275.1-607275.10(2020) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010 Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40:835-849.e8(2022) |
---|